New cancer drug ZL-6201 enters early human testing
NCT ID NCT07374848
First seen Feb 01, 2026 · Last updated Jun 12, 2026 · Updated 16 times
Summary
This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zai Lab Site 02002
RECRUITINGNew York, New York, 10065, United States
-
Zai Lab Site 02003
RECRUITINGLos Angeles, California, 90007, United States
-
Zai Lab Site 02005
RECRUITINGSt Louis, Missouri, 63160, United States
-
Zai Lab Site 02006
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Zai Lab Site 02026
RECRUITINGSarasota, Florida, 34232, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.